Results 131 to 140 of about 74,852 (258)

The DNA damaging revolution : PARP inhibitors and beyond

, 2019
Cancer-specific DNA repair defects are abundant in malignant tissue and present an opportunity to capitalize on these aberrations for therapeutic benefit. Early preclinical data demonstrated the concept of synthetic lethality between BRCA genetic defects
Plummer, R., Ruth Plummer, Yap, T.A., Thomas Helleday, Helleday, T., Timothy A. Yap, Azad, N.S., Nilofer S. Azad   +7 more
core   +1 more source

Ovarian Cancer: Epidemiology, Disease Mechanisms, New Diagnosis and Treatment Strategies, and Research Directions

iNew Medicine, EarlyView.
ABSTRACT Ovarian cancer (OC) continues to be the deadliest gynecological malignancy and a significant cause of cancer‐related mortality among women worldwide. Standard treatment strategies typically entail platinum‐based chemotherapy in conjunction with cytoreductive surgery.
Zunera Khalid, Weirong Fan, Farah Nazir, Yixiang Xing, Tengchuan Jin   +4 more
wiley   +1 more source

The TRPM2–PARP‐1 Axis Involvement in Bisphenol A and Nonylphenol‐Induced Ferroptosis in Trigeminal Ganglion Cells

Journal of Applied Toxicology, EarlyView.
ABSTRACT Environmental contaminants like bisphenol A (BPA) and nonylphenol (NP) are recognized neurotoxicants; however, the molecular mechanisms underlying their impact on sensory ganglia, specifically the trigeminal ganglion (TG), remain critically underexplored.
Betül Yazğan, Musa Tatar, Yener Yazğan, Kıymet Kübra Tüfekci   +3 more
wiley   +1 more source

Poly(ADP-ribose) polymerase (PARP) and PARP inhibitors

PARP-1 protects cells from endogenous and therapeutically inflicted DNA damage. PARP inhibitors have been under development since 1980 and first entered clinical trial in 2003.
Curtin NJ
core  

Synthesis, Cytotoxicity, and Apoptosis‐Associated Cell Death Activity of an Isatin‐Containing Pyrimidine‐Derived Cu(II) Complex

Journal of Applied Toxicology, EarlyView.
ABSTRACT A Cu(II) complex derived from a pyrimidine with the isatin group was synthesized and tested for its cytotoxic effects on A549 lung cancer and MCF‐7 breast cancer cell lines, as well as its effects on apoptosis‐associated cell death and cell cycle regulation in A549 cells. To evaluate cytotoxicity, MTT assays were performed at 24, 48, and 72 h,
Müjgan Kesik Oktay, Cansu Topkaya, Elif Kağa, Yasin Eren, Ramazan Güp   +4 more
wiley   +1 more source

PARP Inhibitors in the Treatment of Ovarian Cancer

Introduction Ovarian cancer is a leading cause of cancer mortality globally due to late-stage diagnosis and limited treatment options. PARP inhibitors have shown promise as effective treatments for recurrent and various stages of ovarian cancer ...
Jagoda Niewiadomska, Magdalena Cieślik-Porębska, Andrzej Paweł Zuzak, Krzysztof Kułak   +3 more
core   +1 more source

Early Dapagliflozin and Melatonin Treatment Ameliorated LV Fibrosis via Suppressing TGF‐β1/Smads and Activating Nrf2‐ARE Signaling in MI Rodent

The Kaohsiung Journal of Medical Sciences, EarlyView.
ABSTRACT This study tested whether combined dapagliflozin (DAPA) and melatonin (Mel) therapy was superior to merely one for ameliorating the left ventricular (LV) fibrosis/remodeling and improving LV ejection fraction (LVEF) in rats after acute myocardial infarction (AMI). In vitro study demonstrated that DAPA treatment significantly suppressed the TGF‐
Jiunn‐Jye Sheu, Jui‐Ning Yeh, Han‐Tan Chai, John Y. Chiang, Chi‐Ruei Huang, Jun Guo, Hon‐Kan Yip   +6 more
wiley   +1 more source

Molecular and genomic advances in breast cancer: A comprehensive review of predictive and therapeutic innovations

Precision Medical Sciences, EarlyView.
Breast cancer subtypes, estrogen receptor‐positive (ER+), HER2‐enriched, and TNBC, are defined by genomic and epigenetic signatures. Multi‐omics profiling, immunotherapy, liquid biopsy, and AI‐driven radiogenomics enable precision medicine. Tools like Oncotype DX and PAM50 support personalized care.
Samina Malik, Arif Malik, Shahzad Ahmad, Hassan Mohsin, Shazia Iqbal   +4 more
wiley   +1 more source

Radiotherapy and Immunotherapy In Hepatocellular Carcinoma: Priming the Tumor Immune Microenvironment From Bench To Bedside

Precision Radiation Oncology, EarlyView.
The dual immunomodulatory network of radiotherapy in hepatocellular carcinoma. Radiotherapy initiates its effects by inducing immunogenic cell death and DNA double‐strand breaks. Immune Activation: Cytosolic DNA from damaged cells activates the cGAS‐STING pathway, triggering IRF3/NF‐κB‐mediated type I interferon production. This enhances dendritic cell
Zhigang Fu, Yang Zhang, Zuomin Wang, Zongjuan Li, Shisuo Du   +4 more
wiley   +1 more source

PARP inhibitors elicit a cellular senescence mediated inflammatory response in homologous recombination proficient cancer cells

Scientific Reports
Poly (ADP-ribose) polymerase (PARP) inhibitors have improved the prognosis of homologous recombination deficient (HRD) ovarian cancer (OC), while effective therapeutic strategies for HR-proficient (HRP) OC still need to be established.
Misato Kamii, Ryo Kamata, Hitoshi Saito, Gaku Yamamoto, Chiaki Mashima, Toyohiro Yamauchi, Takehiro Nakao, Yuta Sakae, Tomoko Yamamori-Morita, Kazuki Nakai, Yumi Hakozaki, Masataka Takenaka, Aikou Okamoto, Akihiro Ohashi   +13 more
doaj   +1 more source